Liver/Biliary Disorders News

Fatty pancreas independently correlated with diabetes mellitus but not hypertension or dyslipidemia, according to research published in Clinical Gastroenterology and Hepatology.

Protara Therapeutics announced results of a study designed to further understand the incidence of intestinal failure-associated liver disease in patients dependent on parenteral nutrition.

Nonalcoholic fatty liver disease correlated with an increased long-term risk for cardiovascular events and may be an independent risk factor for CVD morbidity and mortality, according to research.

Pioglitazone was safe and effective in improving liver histology among patients with nonalcoholic steatohepatitis, according to a presenter at the Digital NAFLD Summit 2021.

Two doses of icosabutate were well tolerated and safe in patients with nonalcoholic steatohepatitis.

Researchers developed a consensus statement that demonstrated the increased need for support in addressing nonalcoholic fatty liver disease as a global public health problem, according to a presentation at the Digital NAFLD Summit 2021.

The temporal change rate of proton density fat fraction and liver stiffness measurement are promising predictors for those at high risk for rapid clinical progression and may improve patient management in those with nonalcoholic fatty liver disease.

Researchers identified more patients with fatty liver disease using novel metabolic dysfunction-associated fatty liver disease criteria compared with nonalcoholic fatty liver disease criteria.

Severe nonalcoholic fatty liver disease may be correlated with Autophagy Related Gene 7 loss-of-function variants, which may impair hepatocellular ballooning and inflammation.

Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma.